List of Excipients in Branded Drug DOVATO

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ViiV Healthcare Company	DOVATO	dolutegravir sodium and lamivudine	49702-246	CELLULOSE, MICROCRYSTALLINE	2030-06-08
ViiV Healthcare Company	DOVATO	dolutegravir sodium and lamivudine	49702-246	HYPROMELLOSE	2030-06-08
ViiV Healthcare Company	DOVATO	dolutegravir sodium and lamivudine	49702-246	MAGNESIUM STEARATE	2030-06-08
ViiV Healthcare Company	DOVATO	dolutegravir sodium and lamivudine	49702-246	MANNITOL	2030-06-08
ViiV Healthcare Company	DOVATO	dolutegravir sodium and lamivudine	49702-246	POLYETHYLENE GLYCOL	2030-06-08
ViiV Healthcare Company	DOVATO	dolutegravir sodium and lamivudine	49702-246	POVIDONE K30	2030-06-08
ViiV Healthcare Company	DOVATO	dolutegravir sodium and lamivudine	49702-246	SODIUM STARCH GLYCOLATE TYPE A CORN	2030-06-08

Dovato Excipient Strategy and Commercial Opportunities

Last updated: October 13, 2026

Dovato is a once-daily, two-drug fixed-dose combination containing dolutegravir 50 mg and lamivudine 300 mg. Its excipient platform is conventional, scalable and cost-efficient: a mannitol-based tablet core with microcrystalline cellulose, povidone, sodium starch glycolate and magnesium stearate, protected by a hypromellose film coating.[1] The strongest commercial opportunities are generic and regional fixed-dose products, pediatric or swallowability adaptations, differentiated packaging, and manufacturing-cost reductions rather than novel excipient claims.

What is Dovato and how is it regulated?

Dovato is marketed by ViiV Healthcare for the treatment of HIV-1 infection in adults and adolescents weighing at least 25 kg, subject to product-label conditions. It combines an integrase strand transfer inhibitor, dolutegravir, with the nucleoside reverse transcriptase inhibitor lamivudine.[1]

Attribute	Dovato profile
Active ingredients	Dolutegravir sodium equivalent to dolutegravir 50 mg; lamivudine 300 mg
Dosage form	Film-coated tablet
Administration	One tablet orally once daily
Core commercial advantage	Two-drug regimen in one tablet
Primary market	Adult HIV-1 treatment
Sponsor	ViiV Healthcare
U.S. FDA approval	February 8, 2019
Key product constraint	Not indicated for patients with known or suspected resistance to either component
Main competitors	Triumeq, Biktarvy, Juluca, generic dolutegravir and lamivudine combinations

The FDA approved Dovato based on clinical studies supporting a two-drug regimen in treatment-naive adults without hepatitis B infection and without relevant resistance concerns.[1] Lamivudine activity against hepatitis B is a regulatory and clinical consideration because Dovato alone is not an adequate hepatitis B treatment regimen.

What excipients are used in Dovato tablets?

The Dovato tablet core uses excipients commonly found in immediate-release oral solid dosage forms. The U.S. prescribing information identifies mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate and magnesium stearate in the tablet core. The film coating contains hypromellose, titanium dioxide, polyethylene glycol and iron oxide.[1]

Excipient	Likely formulation function	Commercial relevance
Mannitol	Diluent and mouthfeel modifier	Supports tablet mass and can improve palatability
Microcrystalline cellulose	Filler and dry-binding aid	Supports compressibility and mechanical strength
Povidone K29/32	Binder	Improves granule and tablet cohesion
Sodium starch glycolate	Superdisintegrant	Promotes tablet breakup and dissolution
Magnesium stearate	Lubricant	Reduces sticking and ejection forces
Hypromellose	Film-forming polymer	Protects the tablet and controls coating appearance
Titanium dioxide	Opacifier and pigment	Provides coating opacity
Polyethylene glycol	Plasticizer and coating aid	Reduces coating brittleness
Iron oxide	Colorant	Supports product identification

The excipient strategy is conservative. Dovato does not depend on an advanced delivery system, modified-release polymer, lipid carrier or enteric coating. That structure reduces manufacturing complexity and gives generic developers multiple options to reproduce the product using established compendial materials.

Why is Dovato’s excipient platform commercially attractive?

Dovato’s formulation creates a low technical barrier for conventional generic development. The principal development challenge is not excipient novelty. It is the simultaneous control of two active pharmaceutical ingredients with different physicochemical properties, dose ratios and regulatory histories.

The 50 mg-to-300 mg strength ratio requires a tablet large enough to accommodate lamivudine while maintaining acceptable swallowability. The formulation must also deliver rapid and consistent dissolution for both actives. A generic manufacturer can pursue direct compression, dry granulation or wet granulation, depending on powder flow, blend uniformity and segregation behavior.

Direct-compression opportunity

A direct-compression platform could reduce equipment use, solvent exposure and processing time. Mannitol and microcrystalline cellulose are compatible with this approach, but the developer must control:

• Blend uniformity at the relatively low dolutegravir loading.
• Segregation between the two active ingredients and excipients.
• Magnesium stearate over-lubrication.
• Tablet tensile strength versus disintegration time.
• Content uniformity across commercial-scale batches.

Dry-granulation opportunity

Roller compaction could improve flow and reduce dependence on aqueous or organic solvents. It may be attractive for manufacturers with high-volume HIV portfolios and established continuous or semi-continuous solid-dose operations.

The main risks are excessive densification, slower dissolution and segregation after milling. A dry-granulated formulation may require a separate optimization of intragranular and extragranular disintegrant levels.

Film-coating opportunity

The coating is unlikely to provide a major barrier to entry. A generic product can use equivalent hypromellose-based systems, subject to color, opacity, identification and regulatory requirements. Potential improvements include lower coating weight, shorter coating cycles and aqueous systems optimized for energy consumption.

What formulation patents protect Dovato?

Dovato’s commercial protection is more likely to depend on active-ingredient patents, combination claims, regulatory exclusivity and method-of-use rights than on a technically difficult excipient platform. The relevant patent analysis must separate:

1. Dolutegravir compound and crystalline-form patents.
2. Dolutegravir and lamivudine combination patents.
3. Dovato-specific formulation or dosage-form patents.
4. Method-of-treatment patents covering two-drug HIV therapy.
5. Pediatric, dosing and patient-selection claims.
6. Manufacturing patents for dolutegravir or the finished combination.

The FDA Orange Book should be reviewed for current Dovato listings, patent numbers and expiration dates before any launch or litigation decision.[2] Orange Book listings can change through patent delisting, corrections, pediatric extensions and regulatory updates.

A key distinction is that the excipients listed in the label are not, by themselves, evidence of enforceable formulation exclusivity. A patent may claim a particular ratio, dissolution profile, process condition, particle-size distribution or excipient combination, but those claims require claim-level analysis.

When does Dovato lose exclusivity?

Dovato’s market-entry timetable depends on the earliest enforceable patent covering the proposed generic product and on the applicant’s regulatory pathway. FDA approval in 2019 does not establish a single commercial patent-expiry date.

Potential exclusivity layers include:

Exclusivity layer	Relevance to Dovato
New chemical entity exclusivity	Dolutegravir had prior FDA approval, so Dovato was not a conventional new-chemical-entity launch
New clinical investigation exclusivity	Combination-specific clinical evidence may support limited regulatory protection where statutory requirements are met
Patent protection	May cover dolutegravir, combinations, formulations, methods or manufacturing
Pediatric exclusivity	Could extend certain listed patents if granted
Orphan exclusivity	Not the primary commercial protection for Dovato
Regulatory data protection outside the U.S.	Depends on jurisdiction and filing history

Commercial entry should be modeled against patent-by-patent expiry rather than a single “Dovato expiry” date. The Orange Book and relevant national registers are the controlling sources for current U.S. and international analysis.[2]

What Paragraph IV challenges could affect Dovato?

A U.S. abbreviated new drug application applicant may file a Paragraph IV certification against an Orange Book-listed Dovato patent. The applicant would assert that the patent is invalid, unenforceable or not infringed. ViiV or the relevant patent holder may then file suit within 45 days, triggering a statutory stay of FDA approval of up to 30 months, subject to litigation developments.[3]

Likely generic strategies include:

• Challenging combination patents while accepting non-infringement of unrelated dolutegravir patents.
• Designing around claimed excipient ratios or manufacturing steps.
• Filing a Paragraph III certification for patents with later expiry.
• Seeking a first-filer position where eligible.
• Launching after settlement under a negotiated date.
• Developing separate dolutegravir and lamivudine products where a fixed-dose combination remains blocked.

No single Paragraph IV strategy guarantees approval or commercial launch. The risk assessment must map each patent claim against the proposed formulation, process and label.

What formulation improvements could create new Dovato opportunities?

Pediatric and adolescent dosage forms

The label includes adolescents above a specified weight threshold, but younger or smaller patients may need alternative strengths, dispersible tablets or oral granules. A pediatric formulation could create a commercial niche if it improves dose flexibility and administration without requiring tablet splitting.

Potential excipient requirements include:

• Improved taste masking.
• Lower tablet mass.
• Rapid dispersion in water.
• Dose flexibility.
• Reduced chalkiness from mannitol or inorganic pigments.
• Compatibility with pediatric administration devices.

A pediatric product would require separate stability, bioavailability and acceptability work. It could also raise new patent opportunities around dose ranges, particle engineering, taste masking and reconstitution behavior.

Dysphagia-focused formulation

A smaller, thinner tablet or dispersible formulation could target patients with swallowing difficulty. The commercial value would depend on whether the dosage form preserves bioequivalence, simplifies administration and avoids a substantial increase in manufacturing cost.

Heat- and humidity-stable packaging

HIV medicines are distributed through global public-health channels, including markets with demanding temperature and humidity conditions. Opportunities include high-barrier blister packs, desiccant-enabled bottles and packaging that improves adherence tracking.

The formulation itself may be chemically stable, but packaging can protect against moisture-driven changes in tablet hardness, dissolution and active-ingredient degradation. Packaging patents may provide more defensible differentiation than conventional excipient substitutions.

Taste and sensory optimization

Taste is less important for standard adult film-coated tablets than for pediatric products, but it becomes central for dispersible and oral-granule formats. Mannitol provides favorable mouthfeel, while polymeric coating, ion-exchange systems or lipid-based taste masking could support a pediatric extension.

How strong is the Dovato patent estate?

The Dovato patent estate should be rated as technically moderate and commercially significant. The conventional tablet composition limits the strength of purely excipient-based differentiation, but the product benefits from the value of dolutegravir, the fixed-dose combination and HIV treatment patents.

Factor	Assessment
Excipient complexity	Low to moderate
Active-ingredient complexity	High for dolutegravir relative to conventional generic APIs
Combination value	High because the product integrates two antiretroviral agents
Design-around potential	Moderate
Bioequivalence burden	Moderate to high
Manufacturing barrier	Moderate
Pediatric extension potential	Meaningful
Biosimilar risk	Not applicable
Small-molecule generic risk	Material after patent barriers fall

Biosimilar competition is not the relevant pathway because Dovato is a chemically synthesized small-molecule product. The principal threat is an ANDA-based generic or a national generic application outside the U.S.

Which companies are positioned to challenge Dovato?

Potential challengers include established generic manufacturers with HIV portfolios, global antiretroviral suppliers and regional manufacturers serving public-health tenders. The most credible challengers are companies with:

• Existing dolutegravir API access.
• Lamivudine manufacturing capacity.
• Bioequivalence infrastructure.
• Experience with fixed-dose HIV combinations.
• WHO prequalification or equivalent procurement credentials.
• Low-cost coating, blistering and high-volume tablet operations.

Competition will likely develop first through separate dolutegravir and lamivudine products, then through fixed-dose combinations where patent and regulatory conditions permit. Public procurement markets may accelerate price erosion even before broad private-sector substitution.

What licensing deals and partnerships matter?

The commercial opportunity extends beyond a standalone generic. Licensing structures may include:

1. Regional licensing of fixed-dose Dovato-like products.
2. API supply agreements for dolutegravir and lamivudine.
3. Technology-transfer arrangements for pediatric formulations.
4. Voluntary licensing for lower-income markets.
5. Contract manufacturing for government tenders.
6. Packaging and distribution partnerships in emerging markets.

The strongest partner profile combines regulatory filing capability with local tender access. A formulation company without API security may face margin compression, while an API supplier without finished-dose registration may capture less value.

What geographic markets offer the best opportunities?

The United States and Western Europe offer the highest unit-price potential but also carry the greatest patent, litigation and substitution risk. Emerging markets offer larger volume opportunities through public tenders, although pricing is lower and local registration requirements vary.

Region	Commercial opportunity	Primary barrier
United States	High-value generic entry	Orange Book patents and Paragraph IV litigation
European Union	Country-specific generic launches	National pricing and reimbursement
Latin America	Fixed-dose and tender supply	Registration fragmentation
Sub-Saharan Africa	High-volume public-health demand	Low prices and procurement qualification
Asia-Pacific	Regional manufacturing and licensing	Diverse regulatory standards
Middle East	Branded-generic opportunities	Local registration and distribution

International analysis must account for national patent term adjustments, supplementary protection certificates, pediatric extensions, compulsory licensing rules and local data-exclusivity periods.

What generic launch scenarios exist for Dovato?

Scenario 1: At-risk U.S. launch

A manufacturer launches after filing a Paragraph IV challenge but before final patent resolution. This can produce first-mover economics but exposes the company to damages, injunction risk and rapid litigation costs.

Scenario 2: Authorized or settlement-based entry

The manufacturer enters on a negotiated date under a settlement agreement. This reduces litigation uncertainty but may delay launch and restrict formulation, labeling or supply terms.

Scenario 3: Post-expiry launch

The company waits for the relevant patent barriers to expire. This lowers legal risk but increases the likelihood of multiple competitors entering simultaneously.

Scenario 4: Regional launch

The company launches in markets where protection is absent, expired or unenforceable. This approach reduces U.S. litigation exposure and can support early volume through public tenders.

Scenario 5: Differentiated pediatric product

A manufacturer targets a less contested segment with a dispersible or taste-masked formulation. The product may command a premium if it improves administration and secures procurement preference.

What is the revenue exposure to Dovato competition?

Revenue exposure is concentrated in the fixed-dose HIV segment. Generic erosion would affect:

• Dovato tablet sales.
• Related dolutegravir franchise economics.
• ViiV’s negotiating position with payers.
• Tender pricing across HIV portfolios.
• Potential switching between two-drug and three-drug regimens.

The impact will vary by channel. Retail and private insurance markets may experience gradual substitution, while government tenders can impose rapid price reductions once a qualified generic supplier enters. GSK identifies Dovato and other dolutegravir-based products as important components of its HIV business.[4]

Key Takeaways

• Dovato uses a conventional, scalable excipient system centered on mannitol, microcrystalline cellulose, povidone, sodium starch glycolate and magnesium stearate.
• The formulation does not present the same technical barrier as a modified-release or complex biologic product.
• The principal development challenge is controlling dolutegravir and lamivudine in one immediate-release tablet.
• Generic opportunities are strongest in fixed-dose combinations, regional markets, pediatric products and cost-optimized manufacturing.
• Patent risk must be analyzed through Orange Book listings, claim scope, expiration dates and litigation history.
• Biosimilar competition is not relevant; small-molecule generic competition is the primary threat.
• Pediatric dispersible products, taste-masked formats and high-barrier packaging offer the clearest differentiated-product opportunities.
• Public-health tenders can create high-volume opportunities but will pressure price and margins.

FAQs

Can a generic manufacturer use the same Dovato excipients?

Yes. Excipients such as mannitol, microcrystalline cellulose, povidone, sodium starch glycolate and magnesium stearate are widely used. The generic product must meet applicable quality, dissolution, bioequivalence and regulatory requirements.

Is Dovato a biologic that can face biosimilar competition?

No. Dovato is a small-molecule fixed-dose combination. Competition follows generic-drug pathways rather than biosimilar pathways.

Does Dovato require a special delivery system?

No. Dovato is an immediate-release film-coated tablet. Its commercial value comes from fixed-dose combination convenience and the pharmacology of dolutegravir and lamivudine.

Could a pediatric Dovato product receive separate patent protection?

Potentially. A pediatric product may support claims directed to dosage, formulation, taste masking, dispersion, administration or patient populations, subject to patentability and statutory requirements.

Are Dovato’s excipients likely to block generic entry?

Usually not by themselves. Generic entry risk is more likely to turn on active-ingredient patents, combination claims, method-of-use claims, regulatory exclusivity and the applicant’s bioequivalence strategy.

References

1. U.S. Food and Drug Administration. (2019). Dovato (dolutegravir sodium and lamivudine) tablets: Prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2017). Abbreviated new drug application submissions: Refuse-to-receive standards.
4. GSK plc. (2024). Annual report 2023.